过去 90 天内没有内部人买入。最近一笔由 Anonymous (Executive member of the board of directors / member of senior management) 披露于 2026年4月28日。
Galderma Group AG:高管交易动态
Galderma Group AG是一家医疗与制药行业的上市公司。其高管通过SIX SER申报股份交易。截至2026年11月6日的十二个月内,共提交29份申报,来自4位高管。
申报中既有买入也有卖出:6笔买入(1位高管,€1672万)与23笔卖出(4位高管,€5983万)。买卖相抵后,净额为卖出€4311万。公开市场买入是最受关注的申报类型,因为高管是用自己的钱购买股份。期内单笔金额最大的是一笔卖出,金额€1065万,于2026年11月5日公布。在买入一方,申报人包括1位高级管理人员。
在30天的窗口内,有1笔买入与另一位高管的买入时间重合。当几位高管在几周之内相继买入时,分析人士称之为集群信号。自最近一次公布的买入(2026年4月28日)以来,已有194天。发布速度很快:至少一半的交易当天就出现在SIX SER的披露中。这个时间差很重要:交易只有在公开后才成为有用的信息。高管卖出的原因很多,可能与公司前景无关,例如税务或遗产安排。
作为参照,同一交易所的中位公司(共179家公司)同期发布了10份申报,而本公司为29份申报。回溯至覆盖起点2024年,高管共申报10笔买入和56笔卖出。
同一行业中,我们的信号近期也捕捉到以下公司的高管买入:Dynavox Group AB和Vetoquinol SA。本摘要仅基于SIX SER的披露信息,不预示股价未来走向。
谁在何时交易
买入卖出内部人买入以来
- Anonymous (Executive member of the board of directors / member of senior management)+10.5%入场价 CHF 171.00 · T+90 收盘 CHF 189.00
- Anonymous (Non-executive member of the board of directors)+48.7%入场价 CHF 63.99 · T+365 收盘 CHF 95.14
入场价为披露次日收盘价,即读者可操作的第一个价格。价格以上市货币计。过往涨跌不代表未来表现。
分析师共识:看涨还是看跌?
分析师对 Galderma Group AG 的评级为买入(看涨),基于 17 位分析师。 平均目标价:CHF 203.71。
该评分只在所属市场内对买入进行排名。仅在经过回测的策略范围内的交易所提供建议仓位;其他市场的信号仍处于观察状态。并非投资建议。
透明的价值 + 质量排名,独立于内部人交易信号。
财务数据
财年 2025财年截至 2025年12月 · cache
- ▼Anonymous (a non-executive member of the board of directors)2M CHF30SIX10,000 股@ CHF 194.930.0044% 占市值36.5% 占其流量ISIN CH1335392721SIX:T1QB500038
- ▼Anonymous (an executive member of the board of directors / member of senior management)2M CHF16SIX10,000 股@ CHF 196.100.0044% 占市值15.2% 占其流量ISIN CH1335392721SIX:T1QB500012
- ▼Anonymous (an executive member of the board of directors / member of senior management)10M CHF0SIX50,000 股@ CHF 195.50ISIN CH1335392721SIX:T1QB500053
- ▼Anonymous (a non-executive member of the board of directors)187,633 CHF29SIX1,101 股@ CHF 170.420.0004% 占市值4.7% 占其流量SIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q8K00082
- ▼Anonymous (a non-executive member of the board of directors)504,900 CHF30SIX3,000 股@ CHF 168.300.0011% 占市值14.5% 占其流量SIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q8I00078
- ▼Anonymous (Non-executive member of the board of directors)504,900 CHF29SIX3,000 股@ CHF 168.300.0011% 占市值2.1% 占其流量ISIN CH1335392721SIX:T1Q8I00086
- ▼Anonymous (an executive member of the board of directors / member of senior management)3M CHF25SIX18,000 股@ CHF 180.000.0087% 占市值12.9% 占其流量SIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q8600033
- ▼Anonymous (a non-executive member of the board of directors)82,455 CHF23SIX475 股@ CHF 173.590.0002% 占市值2.1% 占其流量SIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q8400038
- ▼Anonymous (an executive member of the board of directors / member of senior management)8M CHF29SIX43,436 股@ CHF 180.520.021% 占市值31.4% 占其流量SIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q7V00040
- ▼Anonymous (a non-executive member of the board of directors)3M CHF31SIX15,000 股@ CHF 178.220.0072% 占市值67.8% 占其流量SIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q7V00032
- ▲Anonymous (Executive member of the board of directors / member of senior management)2M CHF23SIX15,000 股@ CHF 161.03330.0065% 占市值2.1% 占其流量ISIN CH1335392721SIX:T1Q4S00084标准退出:2026年7月27日 (T+90)
- ▼Anonymous (Executive member of the board of directors / member of senior management)4M CHF23SIX25,000 股@ CHF 161.88690.011% 占市值3.5% 占其流量ISIN CH1335392721SIX:T1Q4R000F3
- ▲Anonymous (Executive member of the board of directors / member of senior management)3M CHF0SIX20,000 股@ CHF 161.88690.0088% 占市值2.8% 占其流量ISIN CH1335392721SIX:T1Q4R000E6标准退出:2026年7月26日 (T+90)
- ▼Anonymous (Executive member of the board of directors / member of senior management)2M CHF11SIX10,000 股@ CHF 162.85250.0044% 占市值1.4% 占其流量ISIN CH1335392721SIX:T1Q4O00075
- ▲Anonymous (Executive member of the board of directors / member of senior management)2M CHF11SIX15,000 股@ CHF 160.73290.0065% 占市值2.1% 占其流量ISIN CH1335392721SIX:T1Q4O00067标准退出:2026年7月23日 (T+90)
- ▲Anonymous (Executive member of the board of directors / member of senior management)2M CHF11SIX15,000 股@ CHF 148.500.0061% 占市值1.9% 占其流量ISIN CH1335392721SIX:T1Q3U00033标准退出:2026年6月28日 (T+90)
- ▼Anonymous (Executive member of the board of directors / member of senior management)2M CHF23SIX15,000 股@ CHF 149.000.0061% 占市值1.9% 占其流量ISIN CH1335392721SIX:T1Q3Q00049
- ▼Anonymous (Executive member of the board of directors / member of senior management)2M CHF23SIX15,000 股@ CHF 146.100.0060% 占市值1.9% 占其流量ISIN CH1335392721SIX:T1Q3P00041
- ▲Anonymous (Executive member of the board of directors / member of senior management)2M CHF0SIX15,000 股@ CHF 146.000.0060% 占市值1.9% 占其流量ISIN CH1335392721SIX:T1Q3P00033标准退出:2026年6月23日 (T+90)
- ▼Anonymous (Executive member of the board of directors / member of senior management)3M CHF23SIX20,000 股@ CHF 143.17670.0078% 占市值2.5% 占其流量ISIN CH1335392721SIX:T1Q3O00069
- ▲Anonymous (Executive member of the board of directors / member of senior management)3M CHF0SIX20,000 股@ CHF 143.55520.0078% 占市值2.5% 占其流量ISIN CH1335392721SIX:T1Q3O00077标准退出:2026年6月22日 (T+90)
- ▼Anonymous (Non-executive member of the board of directors)70,770 CHF11SIX500 股@ CHF 141.54030.0002% 占市值0.3% 占其流量ISIN CH1335392721SIX:T1Q3I00087
- ▼Anonymous (Non-executive member of the board of directors)263,808 CHF11SIX1,800 股@ CHF 146.560.0007% 占市值1.1% 占其流量ISIN CH1335392721SIX:T1Q3C00064
- ▼Anonymous (Non-executive member of the board of directors)81,176 CHF23SIX500 股@ CHF 162.35230.3% 占其流量ISIN CH1335392721SIX:T1PCN00074
- ▼Anonymous (Executive member of the board of directors / member of senior management)4M CHF23SIX21,266 股@ CHF 166.51863.0% 占其流量ISIN CH1335392721SIX:T1PCA00048
66 条申报中的 25 条
关于 Galderma Group AG
高德美集团股份公司(Galderma Group AG)是一家全球皮肤病学专业公司,在瑞士SIX瑞士交易所(SMI/SPI)上市,股票代码为PY3.F。该公司将自己定位为纯粹的皮肤病学领域领导者,拥有涵盖注射美容、皮肤科护肤和治疗性皮肤病学的综合产品组合。高德美成立于1981年,围绕皮肤健康建立了其特许经营权,并已发展成为一个具有广泛国际影响力的优质、科学主导平台。其总部位于瑞士楚格,2025年,该集团还通过在迈阿密设立新的美国总部加强了其运营足迹,突显了美国市场的战略重要性。([galderma.com](https://www.galderma.com/annual-report-2024?utm_source=openai))
在运营上,高德美围绕三个核心业务线进行组织。在注射美容领域,该公司销售成熟品牌,如神经调节剂中的Dysport/Azzalure和Alluzience,以及透明质酸填充剂和生物刺激剂中的Restylane和Sculptra。在皮肤科护肤领域,Cetaphil是其旗舰消费品牌之一,辅以Alastin。在治疗性皮肤病学领域,高德美解决慢性且具有医学重要性的疾病,包括痤疮、特应性皮炎和结节性痒疹,其较新的资产如Nemluvio正在扩大公司的治疗范围。这种组合为该集团带来了多元化的收入基础,并在医疗和消费渠道中拥有多个增长动力。([galderma.com](https://www.galderma.com/annual-report-2024?utm_source=openai))
展开全文收起
高德美的竞争地位建立在科学信誉、广受认可的品牌组合以及对结构性有吸引力的皮肤病学市场的接触之上。管理层强调其产品线的广度和创新管线的深度是与规模较小、专注度较低的竞争对手相比的关键差异化因素。在地理上,该公司是真正的全球性公司,在北美、欧洲、亚太和国际市场均有商业存在,而美国仍然是主要的盈利和增长引擎。最近的发布和产品线扩展强化了公司的优质化战略及其在医生主导和消费者主导类别中扩大市场份额的能力。([galderma.com](https://www.galderma.com/our-strategy?utm_source=openai))
最近的里程碑对股权故事尤为重要。2024年,高德美于3月22日在SIX瑞士交易所完成了首次公开募股,公司称这是自2017年以来瑞士最大的IPO。2024年全年业绩显示出稳健增长,2025年进一步加速,包括创纪录的销售额以及Nemluvio、Relfydess和Sculptra在中国市场的增长势头。这一势头延续到2026年初,当时公司报告了强劲的第一季度销售增长。对于投资者而言,高德美将防御性医疗保健敞口与高于市场的有机增长潜力以及重要的管线催化剂相结合,使其成为值得关注的重要的瑞士上市医疗保健公司。([galderma.com](https://www.galderma.com/annual-report-2024?utm_source=openai))
同行业近期入选信号
我们的模型当前为推荐列表排序的买入。
全部推荐